Literature DB >> 12369915

Phage display of antibody fragments.

A Pini1, L Bracci.   

Abstract

In recent years, phage display of peptides and proteins has become a very popular method in oncology, immunology, protein engineering and ligand-receptor studies among others. Antibody fragments, as Fabs or single chain Fv, have been among the first proteins to be displayed on the surface of a filamentous bacteriophage with a procedure initially described in 1990 by McCafferty et al. (Nature, 348, 552-554). From that time, molecular biology techniques have allowed the creation of large repertoires of antibody fragments from antibody V genes, bypassing hybrydoma technology and even immunisation. A large number of phage antibody libraries, from which molecules of the desired functional properties can be rapidly selected, have been built and distributed in many laboratories world-wide. Antibody fragments recovered from phage libraries generally show moderate binding strength; with different systems of biopanning binders can be obtained with dissociation constant ranged between 10-(5) to 10-(8) M. Nevertheless, antibody fragments can be furtherly modified to improve affinity or avidity, respectively by mutating crucial residues of complementarity determining regions or by increasing the number of binding sites making dimeric, trimeric or multimeric molecules. Here, we summarise the latest progress in this field, with particular reference to applications of scFv in the diagnosis and therapy of solid tumours and in the molecular mimicry of viral antigens and membrane receptors. In fact, the production of artificial protein epitopes by phage antibodies is becoming a valid system to overcome problems caused by difficult cloning and low expression of particular recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12369915     DOI: 10.2174/1389203003381397

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  20 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

3.  Broad-host-range plasmid pJB658 can be used for industrial-level production of a secreted host-toxic single-chain antibody fragment in Escherichia coli.

Authors:  H Sletta; A Nedal; T E V Aune; H Hellebust; S Hakvåg; R Aune; T E Ellingsen; S Valla; T Brautaset
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

4.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

5.  Efficient amplification of light and heavy chain variable regions and construction of a non-immune phage scFv library.

Authors:  Maneerat Koohapitagtam; Suang Rungpragayphan; Ratchanee Hongprayoon; Wichai Kositratana; Theerapol Sirinarumitr
Journal:  Mol Biol Rep       Date:  2009-06-25       Impact factor: 2.316

Review 6.  [Monoclonal antibodies. Principles, generation, application, and side effects].

Authors:  U Sack; F Emmrich
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

7.  Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus.

Authors:  Sergey A Shiryaev; Ilian A Radichev; Boris I Ratnikov; Alexander E Aleshin; Katarzyna Gawlik; Boguslaw Stec; Christian Frisch; Achim Knappik; Alex Y Strongin
Journal:  Biochem J       Date:  2010-04-14       Impact factor: 3.857

8.  Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.

Authors:  Irina V Balyasnikova; Derek A Wainwright; Elena Solomaha; Gina Lee; Yu Han; Bart Thaci; Maciej S Lesniak
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

9.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

Review 10.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.